ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone Prescriptions Declined after FDA Warning
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 115080" data-attributes="member: 3"><p><strong>The state of testosterone therapy since the FDA's 2015 labeling changes: Indications and cardiovascular risk</strong></p><p></p><p></p><p></p><p>Summary</p><p>Objective</p><p>A label change in testosterone (T) products in March 2015 followed a highly publicized FDA advisory committee meeting in September 2014. Changes included a warning of possible increased cardiovascular (CV) risks and restriction of indicated populations to younger men with a limited set of known aetiologies of testosterone deficiency (TD). These changes greatly impacted clinical practice and public perception of T therapy (TTh). Our aim was to review these changes in the light of subsequently published studies.</p><p></p><p>Design</p><p>We identified 23 studies through June 2017, including 12 clinical trials and 11 observational studies. The Testosterone Trials included 790 men aged 65 years and older with TD without known aetiology, assigned to 1&#8208;year T gel or placebo.</p><p></p><p>Results</p><p>Demonstrated benefits of T included sexual activity and desire, physical activity and mood. There were 9 major adverse CV events (MACE) in the T arm and 16 in the placebo arm. No study reported increased MACE with TTh. A 3&#8208;year RCT showed no difference in carotid atherosclerosis. Several large observational studies reported reduced CV events with TTh, including one showing progressively reduced CV and mortality risk with greater duration of TTh. Men whose serum T normalized with TTh had reduced risk of MI and death compared with men whose T levels failed to normalize.</p><p></p><p>Conclusion</p><p><strong>We conclude that existing evidence fails to support increased CV risk with TTh; on the contrary, there is evidence suggestive of real&#8208;world CV benefits. Finally, existing evidence provides benefits of TTh in older men without known </strong><strong>aetiology</strong><strong> for T deficiency.</strong></p><p></p><p><a href="https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13589" target="_blank">FULL PAPER</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 115080, member: 3"] [B]The state of testosterone therapy since the FDA's 2015 labeling changes: Indications and cardiovascular risk[/B] Summary Objective A label change in testosterone (T) products in March 2015 followed a highly publicized FDA advisory committee meeting in September 2014. Changes included a warning of possible increased cardiovascular (CV) risks and restriction of indicated populations to younger men with a limited set of known aetiologies of testosterone deficiency (TD). These changes greatly impacted clinical practice and public perception of T therapy (TTh). Our aim was to review these changes in the light of subsequently published studies. Design We identified 23 studies through June 2017, including 12 clinical trials and 11 observational studies. The Testosterone Trials included 790 men aged 65 years and older with TD without known aetiology, assigned to 1‐year T gel or placebo. Results Demonstrated benefits of T included sexual activity and desire, physical activity and mood. There were 9 major adverse CV events (MACE) in the T arm and 16 in the placebo arm. No study reported increased MACE with TTh. A 3‐year RCT showed no difference in carotid atherosclerosis. Several large observational studies reported reduced CV events with TTh, including one showing progressively reduced CV and mortality risk with greater duration of TTh. Men whose serum T normalized with TTh had reduced risk of MI and death compared with men whose T levels failed to normalize. Conclusion [B]We conclude that existing evidence fails to support increased CV risk with TTh; on the contrary, there is evidence suggestive of real‐world CV benefits. Finally, existing evidence provides benefits of TTh in older men without known [/B][B]aetiology[/B][B] for T deficiency.[/B] [URL="https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13589"]FULL PAPER[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone Prescriptions Declined after FDA Warning
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top